Japanese study involving Athersys’ MultiStem technology has enrolled its first patient

Story excerpt provided by Crain’s Cleveland Business.

Written by Scott Suttell.

Cleveland biotechnology company Athersys Inc. (Nasdaq: ATHX) announced that Healios K.K., its partner in Japan, has enrolled the first patient in a study evaluating MultiStem cell therapy treatment of patients who have suffered an ischemic stroke.

Athersys said in a Nov. 15 news release that the Healios study, known as TREASURE., is designed to enroll a total of 220 patients with moderate to severe strokes.

Click here to read the complete article.

Originally published November 16, 2017.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: